Compare Enveric Biosciences Inc (ENVB) vs Nasdaq Inc (NDAQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Nasdaq Inc — how do they compare? Enveric Biosciences Inc trades at $1.48 (market cap $6.80M), while Nasdaq Inc trades at $93.61 (market cap $51.63B). The key difference: Nasdaq Inc is far larger — about 7592.6× Enveric Biosciences Inc's market cap, and Nasdaq Inc pays a 1.26% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Nasdaq Inc for 125 Days on average.
| ENVB | NDAQ | |
|---|---|---|
Market Cap | $6.80M | $51.63B |
Volume | 64,867 | 2,668,175 |
Sector | Health | Financials |
52-Week High | $10.80 | $100.98 |
52-Week Low | $1.27 | $76.85 |
Typical Hold Time | 14 Days | 125 Days |
Enterprise Value | -$1.49M | $58.09B |
Dividend Yield | — | 1.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.45, down 3.01% on the day, with a bearish technical signal driven by moving averages. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten quarterly EPS expectations. Recent positive developments include a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in investor conferences.
The outlook is mixed; analyst consensus is 75% buy with strong earnings beats, but high negative ROE/ROA and operational cash burn pose significant risks. Investment opportunity hinges on successful drug development, while key risks include funding needs and clinical trial outcomes.
Nasdaq Inc. (NDAQ) trades at $91.93, down 0.37% on the day, with strong fundamentals including 2025 revenue of $8.26B and net income of $1.79B. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 expected at $1.02 EPS. Technical indicators show a bearish overall signal despite bullish moving averages, with key support at $90 and resistance at $92-94.
NDAQ presents a compelling investment case with 61% analyst buy ratings and a $110.43 consensus price target, representing 20% upside. Strong profitability metrics (22.5% net margin, 16.5% ROE) and growing Financial Technology business offset technical weakness. Risks include market volatility exposure and competitive pressures in exchange services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →
